Pro Medicus FY26 slides: record growth, margins near 75%

Pro Medicus reported FY26 revenue of A$261.7m (+22.9% reported) and underlying revenue growth of +28.4% in constant currency, with EBIT up 24.4% to A$196.1m and EBIT margin expanding 90 bps to 74.9%. Cash rose 23.8% to A$216.1m, it holds zero debt, and declared a 69.0 cents/share fully franked dividend (+25.5%). With A$1.3bn in 5-year forward recurring revenue contracts (+41.3%) and major wins including a A$170m UCHealth Colorado 10-year deal and A$548m total contract value, shares jumped ~13% on the results.

Analysis

PMCUF is increasingly a recurring-revenue compounding story, not a one-off software win story. The key second-order effect is pricing power: renewals at higher per-transaction economics and broader module adoption imply that each installed hospital becomes more valuable over time, which is the main reason the market keeps rewarding the multiple. That also makes the platform a distribution gatekeeper for third-party AI and specialty workflows; niche point solutions are less likely to win standalone access if PMCUF owns the workflow layer.

The near-term risk is not the balance sheet, it is expectation density. After a sharp gap-up, the stock will trade on proof that the new contracts convert on schedule and that the new reporting/pathology modules actually lift revenue per exam rather than just adding product noise. Any slippage in go-lives, evidence of procurement pushback on renewal pricing, or a stronger AUD masking reported growth can trigger a fast de-rating over 1-3 months even if the fundamental thesis is intact.

Contrarian view: the market may be underestimating how durable the moat is, but it may also be overestimating how quickly the next leg of growth is monetized. The AI narrative is valuable only if attach rates are measurable; otherwise it is optionality embedded in a rich multiple. Six to eighteen months out, the stock is still levered to execution, but the asymmetry shifts from operational to valuation risk if growth slips below the low-30s constant-currency path.

Key Decisions for Investors

• Do not chase PMCUF after the earnings gap; wait for a 3-5% pullback or a multi-day consolidation before adding, because the first move likely already priced in most of the headline beat.
• If already long PMCUF, trim 20-30% into strength and keep the remainder as a core position; the thesis is strong, but the current valuation leaves little margin for any implementation delay.
• Use a 3-6 month call spread on PMCUF instead of outright stock if you want upside exposure with limited multiple risk; the next catalyst is cohort go-live cadence, not immediate rerating.
• Watch the next two implementation updates and FY27 quarterly run-rate closely; if constant-currency growth slips below ~25% or management flags any cohort delay, treat that as a thesis break and reduce exposure.
• For relative value, pair a PMCUF long with a short in a higher-multiple healthcare software name if you need valuation hedge; the long remains defensible, but the short leg should offset sector-wide multiple compression risk.